Esophageal String Test Monitoring to Monitor Eosinophilic Esophagitis During Oral Immunotherapy
Monitoring Eosinophilic Esophagitis During Food Oral Immunotherapy Using Esophageal String Test
Children's Hospital of Philadelphia
75 participants
Apr 1, 2024
OBSERVATIONAL
Conditions
Summary
Patients with IgE mediated food Allergy have elevated risk of eosinophilic esophagitis, and new therapies like oral immunotherapy (OIT) carry additional risk of Eosinophilic Esophagitis (EoE). The goal of this study is to investigate the Esophageal String Test (EST) as a screening tool for Eosinophilic Esophagitis (EoE) during OIT therapy. Investigators will compare the efficacy of the Esophageal String Test to symptom assessment using a validated patient reported symptom questionnaire, the Pediatric Eosinophilic Esophagitis Symptom Score (PEESS) v2.0. Investigators will utilize these tools to screen patients at their baseline visit prior to the start of OIT, then at the 3- and 6-month OIT follow-up visits.
Eligibility
Inclusion Criteria7
- An individual must meet all of the following criteria:
- Male or female, aged 7 to 18 years old, inclusive
- Have a history of Immunoglobulin (IgE)-mediated food allergy
- Considering using oral immunotherapy (OIT) for food allergies at CHOP°
- Able \& willing to swallow the esophageal capsule
- Parental/guardian permission (informed consent) and if appropriate, child assent.
- Willing to comply with all study procedures and be available for the duration of the study.
Exclusion Criteria13
- Known or expected need for MRI imaging during the study period
- Known connective tissue disease
- Known eosinophilic disorder including any eosinophilic gastrointestinal disorder and hypereosinophilic disorder
- Past history of caustic ingestion or other esophageal injury
- History of esophageal surgery or dilation (i.e.: tracheoesophageal fistula repair)
- History of gastrointestinal motility disorder including esophageal achalasia
- History of inflammatory bowel disease
- Unwilling or unable to swallow the EST
- Oral or intravenous steroids in the preceding 60 days (not including swallowed topical fluticasone, budesonide, etc.)
- Participation in a clinical study that may interfere with participation in this study
- Pregnant or lactating females
- Limited English proficiency
- Parents/guardians or subjects who, in the opinion of the Investigator, may be non-compliant with study schedules or procedures.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The EnteroTracker® capsule is supplied in pouches, each pouch containing a single capsule. The device is comprised of an ingestible capsule that contains a weighted ball and a highly absorbent nylon string. The looped portion of the string is secured externally to the patient's cheek and the rest of the capsule is swallowed by the patient.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06389994